JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
+$3.46B |
| 2 |
Microsoft
MSFT
|
+$2.83B |
| 3 |
Eli Lilly
LLY
|
+$2.1B |
| 4 |
Broadcom
AVGO
|
+$1.33B |
| 5 |
Stryker
SYK
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$3.18B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$2.39B |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$2.35B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$2.07B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.5B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.04% |
| 2 | Technology | 20.48% |
| 3 | Healthcare | 9.65% |
| 4 | Financials | 9.27% |
| 5 | Consumer Discretionary | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4301
Lineage Cell Therapeutics
LCTX
$235M
| $792K | ﹤0.01% |
727,013
+17,535
| +2% | +$19.2K |
2017 Q4
24 quarters
|
|
4302
NatWest
NWG
$69.9B
| $788K | ﹤0.01% |
139,888
+107,901
| +337% | +$573K |
2014 Q2
38 quarters
|
|
|
YALA
4303
Yalla Group
YALA
$808M
| $785K | ﹤0.01% |
128,123
+82,479
| +181% | +$468K |
2023 Q3
1 quarter
|
|
4304
Lufax Holding
LU
$884M
| $785K | ﹤0.01% |
255,739
-130,910
| -34% | -$488K |
2020 Q4
12 quarters
|
|
|
CFLT
4305
CALL
DELISTED
Confluent
CFLT
| $782K | ﹤0.01% |
33,400
-3,100
| -8% | -$74.9K |
2023 Q3
1 quarter
|
|
4306
ProShares MSCI Emerging Markets Dividend Growers ETF
EMDV
$7.11M
| $781K | ﹤0.01% |
+17,783
| New | +$760K |
2023 Q4
0 quarters
|
|
4307
Principal Exchange-Traded Funds Principal US Mega-Cap ETF
USMC
$5.34B
| $780K | ﹤0.01% |
+16,682
| New | +$738K |
2023 Q4
0 quarters
|
|
4308
CALL
Datadog
DDOG
$99.5B
| $777K | ﹤0.01% |
6,400
+4,300
| +205% | +$443K |
2023 Q2
2 quarters
|
|
4309
Summit Therapeutics
SMMT
$13.4B
| $773K | ﹤0.01% |
296,205
+82,391
| +39% | +$169K |
2020 Q3
13 quarters
|
|
|
CNGL
4310
DELISTED
Canna-Global Acquisition Corp. Class A Common Stock
CNGL
| $773K | ﹤0.01% |
+71,037
| New | +$770K |
2023 Q4
0 quarters
|
|
|
IGR
4311
CBRE Global Real Estate Income Fund
IGR
$589M
| $771K | ﹤0.01% |
47,325
+35,722
| +308% | +$491K |
2022 Q2
6 quarters
|
|
|
OPRA
4312
Opera Ltd
OPRA
$1.57B
| $770K | ﹤0.01% |
58,214
+16,171
| +38% | +$191K |
2021 Q4
8 quarters
|
|
4313
Miller Industries
MLR
$617M
| $770K | ﹤0.01% |
18,209
+10,597
| +139% | +$417K |
2017 Q4
24 quarters
|
|
4314
Novavax
NVAX
$1.73B
| $769K | ﹤0.01% |
160,214
+25,687
| +19% | +$157K |
2014 Q3
37 quarters
|
|
|
FFIC
4315
DELISTED
Flushing Financial
FFIC
| $768K | ﹤0.01% |
46,582
+20,857
| +81% | +$291K |
2013 Q2
42 quarters
|
|
4316
Global X SuperDividend US ETF
DIV
$764M
| $766K | ﹤0.01% |
44,568
+9,796
| +28% | +$159K |
2020 Q2
14 quarters
|
|
4317
NRC Health Common Stock
NRC
$450M
| $762K | ﹤0.01% |
19,260
+1,299
| +7% | +$54.4K |
2017 Q4
24 quarters
|
|
4318
PUT
Affirm
AFRM
$23.9B
| $762K | ﹤0.01% |
+15,500
| New | +$448K |
2023 Q4
0 quarters
|
|
4319
CALL
Performance Food Group
PFGC
$14.7B
| $761K | ﹤0.01% |
+11,000
| New | +$676K |
2023 Q4
0 quarters
|
|
4320
State Street SPDR S&P Transportation ETF
XTN
$307M
| $759K | ﹤0.01% |
9,095
-701
| -7% | -$52.5K |
2017 Q1
27 quarters
|
|
4321
Xeris Biopharma Holdings
XERS
$1.66B
| $758K | ﹤0.01% |
322,436
+205,480
| +176% | +$379K |
2018 Q3
21 quarters
|
|
4322
CALL
ResMed
RMD
$30.8B
| $757K | ﹤0.01% |
4,400
| – | – |
2023 Q3
1 quarter
|
|
|
FNA
4323
DELISTED
Paragon 28, Inc.
FNA
| $755K | ﹤0.01% |
60,761
+9,884
| +19% | +$105K |
2021 Q4
8 quarters
|
|
4324
Magnachip Semiconductor
MX
$134M
| $751K | ﹤0.01% |
100,196
+50,346
| +101% | +$368K |
2020 Q1
15 quarters
|
|
4325
Kayne Anderson Energy Infrastructure Fund
KYN
$2.35B
| $750K | ﹤0.01% |
85,410
+71,273
| +504% | +$596K |
2022 Q4
4 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2023 Portfolio in Review
As of Q4 2023, JP Morgan Chase held 8,129 positions worth $1.04T, up 15% from $906B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
JP Morgan Chase's Q4 2023 filing shows 701 new, 3,661 increased, 2,247 reduced and 617 closed positions. Its largest new stake was JPMorgan US Tech Leaders ETF: 3,149,069 shares worth $185M. The largest sale was Vanguard S&P 500 ETF, an estimated $3.18B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q4 2023 buy was JPMorgan US Tech Leaders ETF: 3,149,069 shares worth $185M.
- JP Morgan Chase added most to Vanguard Intermediate-Term Corporate Bond ETF in Q4 2023, an estimated $3.46B increase.
- JP Morgan Chase's biggest Q4 2023 reduction was Vanguard S&P 500 ETF, cutting an estimated $3.18B.
- JP Morgan Chase fully exited Activision Blizzard in Q4 2023, selling an estimated $1.06B.
- JP Morgan Chase's ten largest holdings make up 20% of its $1.04T portfolio in Q4 2023.
- JP Morgan Chase opened 701 new positions and closed 617 in Q4 2023.
- JP Morgan Chase's portfolio value rose 15% quarter-over-quarter to $1.04T.
Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.